Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $342.73 million. The enterprise value is $1.18 billion.
Important Dates
The last earnings date was Tuesday, February 24, 2026, after market close.
| Earnings Date | Feb 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 111.64 million shares outstanding. The number of shares has decreased by -0.41% in one year.
| Current Share Class | 111.64M |
| Shares Outstanding | 111.64M |
| Shares Change (YoY) | -0.41% |
| Shares Change (QoQ) | -2.15% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 95.62% |
| Float | 92.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.89 |
| PS Ratio | 0.18 |
| Forward PS | 0.14 |
| PB Ratio | 0.82 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 71.61 |
| P/OCF Ratio | 8.77 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 13.36, with an EV/FCF ratio of 247.81.
| EV / Earnings | n/a |
| EV / Sales | 0.63 |
| EV / EBITDA | 13.36 |
| EV / EBIT | n/a |
| EV / FCF | 247.81 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 2.38.
| Current Ratio | 1.31 |
| Quick Ratio | 1.20 |
| Debt / Equity | 2.38 |
| Debt / EBITDA | 10.69 |
| Debt / FCF | 208.14 |
| Interest Coverage | -0.08 |
Financial Efficiency
Return on equity (ROE) is -66.54% and return on invested capital (ROIC) is -0.29%.
| Return on Equity (ROE) | -66.54% |
| Return on Assets (ROA) | -0.12% |
| Return on Invested Capital (ROIC) | -0.29% |
| Return on Capital Employed (ROCE) | -0.29% |
| Weighted Average Cost of Capital (WACC) | 4.83% |
| Revenue Per Employee | $446,721 |
| Profits Per Employee | -$137,953 |
| Employee Count | 4,200 |
| Asset Turnover | 0.84 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -126,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.19% in the last 52 weeks. The beta is 0.23, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -67.19% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 6.80 |
| Relative Strength Index (RSI) | 42.88 |
| Average Volume (20 Days) | 3,465,538 |
Short Selling Information
The latest short interest is 20.21 million, so 18.10% of the outstanding shares have been sold short.
| Short Interest | 20.21M |
| Short Previous Month | 19.13M |
| Short % of Shares Out | 18.10% |
| Short % of Float | 21.74% |
| Short Ratio (days to cover) | 6.29 |
Income Statement
In the last 12 months, Evolent Health had revenue of $1.88 billion and -$579.40 million in losses. Loss per share was -$5.07.
| Revenue | 1.88B |
| Gross Profit | 399.88M |
| Operating Income | -4.44M |
| Pretax Income | -534.64M |
| Net Income | -579.40M |
| EBITDA | 88.22M |
| EBIT | -4.44M |
| Loss Per Share | -$5.07 |
Full Income StatementBalance Sheet
The company has $151.86 million in cash and $989.70 million in debt, with a net cash position of -$837.84 million or -$7.50 per share.
| Cash & Cash Equivalents | 151.86M |
| Total Debt | 989.70M |
| Net Cash | -837.84M |
| Net Cash Per Share | -$7.50 |
| Equity (Book Value) | 415.19M |
| Book Value Per Share | 3.72 |
| Working Capital | 121.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $38.84 million and capital expenditures -$34.09 million, giving a free cash flow of $4.76 million.
| Operating Cash Flow | 38.84M |
| Capital Expenditures | -34.09M |
| Free Cash Flow | 4.76M |
| FCF Per Share | $0.04 |
Full Cash Flow StatementMargins
Gross margin is 21.31%, with operating and profit margins of -0.24% and -28.49%.
| Gross Margin | 21.31% |
| Operating Margin | -0.24% |
| Pretax Margin | -28.50% |
| Profit Margin | -28.49% |
| EBITDA Margin | 4.70% |
| EBIT Margin | -0.24% |
| FCF Margin | 0.25% |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.41% |
| Shareholder Yield | 0.41% |
| Earnings Yield | -170.16% |
| FCF Yield | 1.40% |
Analyst Forecast
The average price target for Evolent Health is $7.93, which is 158.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.93 |
| Price Target Difference | 158.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 18.83% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 0.49 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.49 |
| Piotroski F-Score | 4 |
